The glycome of normal and malignant plasma cells

Thomas M Moehler, Anja Seckinger, Dirk Hose, Mindaugas Andrulis, Jèrôme Moreaux, Thomas Hielscher, Martina Willhauck-Fleckenstein, Anette Merling, Uta Bertsch, Anna Jauch, Hartmut Goldschmidt, Bernard Klein, Reinhard Schwartz-Albiez

Onderzoeksoutput: Articlepeer review

9 Citaten (Scopus)


The glycome, i.e. the cellular repertoire of glycan structures, contributes to important functions such as adhesion and intercellular communication. Enzymes regulating cellular glycosylation processes are related to the pathogenesis of cancer including multiple myeloma. Here we analyze the transcriptional differences in the glycome of normal (n = 10) and two cohorts of 332 and 345 malignant plasma-cell samples, association with known multiple myeloma subentities as defined by presence of chromosomal aberrations, potential therapeutic targets, and its prognostic impact. We found i) malignant vs. normal plasma cells to show a characteristic glycome-signature. They can ii) be delineated by a lasso-based predictor from normal plasma cells based on this signature. iii) Cytogenetic aberrations lead to distinct glycan-gene expression patterns for t(11;14), t(4;14), hyperdiploidy, 1q21-gain and deletion of 13q14. iv) A 38-gene glycome-signature significantly delineates patients with adverse survival in two independent cohorts of 545 patients treated with high-dose melphalan and autologous stem cell transplantation. v) As single gene, expression of the phosphatidyl-inositol-glycan protein M as part of the targetable glycosyl-phosphatidyl-inositol-anchor-biosynthesis pathway is associated with adverse survival. The prognostically relevant glycome deviation in malignant cells invites novel strategies of therapy for multiple myeloma.

Originele taal-2English
Aantal pagina's13
TijdschriftPLOS ONE
Nummer van het tijdschrift12
StatusPublished - 2013


Duik in de onderzoeksthema's van 'The glycome of normal and malignant plasma cells'. Samen vormen ze een unieke vingerafdruk.

Citeer dit